Annual report
4978.TEDINET S100R5G8
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥2.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥1.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥356m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | −¥647m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | −¥120m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥507m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥789m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥892m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥627m | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥304m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥574m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥305m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥575m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥813m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.0bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥601m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥305m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | −¥575m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥8.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥8.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥6.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥7.5bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥781m | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥845m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.4bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥6.1bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥7.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥141m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥246m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥649m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥690m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥555m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥483m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥7m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-3.62 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-11.38 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.27 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.79 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥89.01 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥88.11 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥75.17 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥84.76 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥99.5 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 90.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.7% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 92 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 98 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 106 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 113 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 111 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥1.6bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥1.3bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥606m | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥429m | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥492m | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥337m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | −¥471m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | −¥112m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥382m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥559m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥564m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥191m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥296m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥540m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥297m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥541m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥997m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥905m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥213m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥8.2bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥6.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.9bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.7bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥522m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥641m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥7.9bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥7.5bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥5.7bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥6.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.4bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-3.52 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.13 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.96 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.71 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.12 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥92.42 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.73 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥79.12 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.69 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥104.28 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 93.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.1% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 85,141,191 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 82,270,891 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 71,667,391 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 71,406,891 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 71,066,391 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 28 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 31 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 34 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 34 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 30 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥3m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥11m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥7.5bn |
| Reconciling Itemsreconciling | segment ordinary income | 2022-04-01 → 2023-03-31 | −¥543m |
| Medical Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥121m |
| Medical Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥30m |
| Medical Businessreportable segment | employees | at 2023-03-31 | 6 pure |
| Medical Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥936m |
| Medical Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥936m |
| Medical Businessreportable segment | segment assets | at 2023-03-31 | ¥133m |
| Medical Businessreportable segment | segment ordinary income | 2022-04-01 → 2023-03-31 | ¥56m |
| Research Support Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥37m |
| Research Support Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥5m |
| Research Support Businessreportable segment | employees | at 2023-03-31 | 67 pure |
| Research Support Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Research Support Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Research Support Businessreportable segment | segment assets | at 2023-03-31 | ¥683m |
| Research Support Businessreportable segment | segment ordinary income | 2022-04-01 → 2023-03-31 | ¥367m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥158m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥35m |
| —segment total | employees | at 2023-03-31 | 73 pure |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| —segment total | segment assets | at 2023-03-31 | ¥815m |
| —segment total | segment ordinary income | 2022-04-01 → 2023-03-31 | ¥423m |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥1m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥15m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥7.3bn |
| Reconciling Itemsreconciling | segment ordinary income | 2021-04-01 → 2022-03-31 | −¥579m |
| Medical Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥20m |
| Medical Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥26m |
| Medical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥854m |
| Medical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥854m |
| Medical Businessreportable segment | segment assets | at 2022-03-31 | ¥274m |
| Medical Businessreportable segment | segment ordinary income | 2021-04-01 → 2022-03-31 | −¥63m |
| Research Support Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥26m |
| Research Support Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥15m |
| Research Support Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Research Support Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Research Support Businessreportable segment | segment assets | at 2022-03-31 | ¥477m |
| Research Support Businessreportable segment | segment ordinary income | 2021-04-01 → 2022-03-31 | ¥135m |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥47m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥42m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| —segment total | segment assets | at 2022-03-31 | ¥750m |
| —segment total | segment ordinary income | 2021-04-01 → 2022-03-31 | ¥72m |
| Medical Businessreportable segment | employees | at 2023-03-31 | 6 pure |
| Research Support Businessreportable segment | employees | at 2023-03-31 | 17 pure |
| —segment total | employees | at 2023-03-31 | 23 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,485
| Item | Context | Value | Unit |
|---|---|---|---|
| Total assets (5-year summary) | Prior1YearInstant | 8095322000 | JPY |
| Total assets (5-year summary) | CurrentYearInstant | 8355848000 | JPY |
| Net assets per share (5-year summary) | Prior4YearInstant | 99.50 | |
| Net assets per share (5-year summary) | Prior3YearInstant | 84.76 | |
| Net assets per share (5-year summary) | Prior2YearInstant | 75.17 | |
| Net assets per share (5-year summary) | Prior1YearInstant | 88.11 | |
| Net assets per share (5-year summary) | CurrentYearInstant | 89.01 | |
| Basic earnings loss per share (5-year summary) | Prior4YearDuration | -8.79 | |
| Basic earnings loss per share (5-year summary) | Prior3YearDuration | -14.27 | |
| Basic earnings loss per share (5-year summary) | Prior2YearDuration | -11.38 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | -7.57 | |
| Basic earnings loss per share (5-year summary) | CurrentYearDuration | -3.62 | |
| Diluted earnings per share (5-year summary) | Prior4YearDuration | － | |
| Diluted earnings per share (5-year summary) | Prior3YearDuration | － | |
| Diluted earnings per share (5-year summary) | Prior2YearDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior4YearInstant | 0.937 | |
| Equity to asset ratio (5-year summary) | Prior3YearInstant | 0.923 | |
| Equity to asset ratio (5-year summary) | Prior2YearInstant | 0.890 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.895 | |
| Equity to asset ratio (5-year summary) | CurrentYearInstant | 0.907 | |
| Rate of return on equity (5-year summary) | Prior4YearDuration | － | |
| Rate of return on equity (5-year summary) | Prior3YearDuration | － | |
| Rate of return on equity (5-year summary) | Prior2YearDuration | － | |
| Rate of return on equity (5-year summary) | Prior1YearDuration | － | |
| Rate of return on equity (5-year summary) | CurrentYearDuration | － | |
| Price earnings ratio (5-year summary) | Prior4YearDuration | － | |
| Price earnings ratio (5-year summary) | Prior3YearDuration | － | |
| Price earnings ratio (5-year summary) | Prior2YearDuration | － | |
| Price earnings ratio (5-year summary) | Prior1YearDuration | － | |
| Price earnings ratio (5-year summary) | CurrentYearDuration | － | |
| Net cash provided by used in operating activities (5-year summary) | Prior4YearDuration | -554831000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior3YearDuration | -689803000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior2YearDuration | -648883000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | -246244000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration | -140534000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration | -2308145000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration | 1217887000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration | -1416764000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -2144054000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration | -1087496000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration | 1381166000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration | 6566000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration | 4410000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 2384754000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYearDuration | 482872000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior4YearInstant | 4112750000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior3YearInstant | 4585626000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior2YearInstant | 2601406000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |